Rachel L. Hill, PhD, MS: Metabolic Bone Disease and Fracture Risk in Pancreatitis in KY
Assistant Research Professor
Division of Biomedical Informatics
Dept of Internal Medicine
University of Kentucky

Malik Khurram Khan, MD FCCP: Improve care for our Alpha 1 antitrypsin Deficiency(AATD) patients by building a new AATD multidisciplinary clinic at University of Kentucky, recognized as a ‘Clinical Resource center’( CRC) with the Alpha-1 foundation
Medical Director, UK Healthcare Pulmonary Rehabilitation Center
Advanced COPD and Alpha 1 Antitrypsin Specialty Clinic
Associate Professor of Medicine
Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine
University of Kentucky College of Medicine

 

Armaghan-e-Rehman Mansoor, MBBS: Hepatitis B Screening at Bluegrass Care Clinic
Assistant Professor, Infectious Diseases
University of Kentucky 

Mark Rudy, MD: UK Glomerular Diseases Center of Excellence
Assistant Professor
Division of Nephrology, Bone and Mineral Metabolism 
University of Kentucky 

Preetha Shridas, PhD: Plasma Cholesterol and Lipoprotein Profiles in Sepsis: Associations with Mortality and Clinical Outcomes in the ARDSNetSAILS Trial
Associate Professor
Internal Medicine, Division of Endocrinology
Barnstable Brown Diabetes Center
University of Kentucky
 

In person and via Zoom

Upon completion of this activity, participants will be able to:

• Describe strategies to improve access to care for patients with glomerular diseases within the University of Kentucky referral network.
• Review future directions and scalable lessons from the Hepatitis B screening/vaccination initiative
• Identify differences in plasma lipoprotein profiles between sepsis survivors and non-survivors
• Describe the clinical impact and management considerations of Alpha-1 Antitrypsin Deficiency (AATD)
• Describe the relationship between pancreatitis, metabolic bone disease, and fracture risk

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant tif the educational content an individual can control is related to the business lines or products of the ineligible company.

The planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose: none

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off- label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off label uses.

Disclosure of relationships is not intended to suggest or condone commercial bias in any presentations, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation